Literature DB >> 7492623

Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions.

P Vandenberghe1, M A Boogaerts.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7492623     DOI： 10.1007/bf01744370

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  61 in total

1.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

2.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.

Authors:  R A Zittoun; F Mandelli; R Willemze; T de Witte; B Labar; L Resegotti; F Leoni; E Damasio; G Visani; G Papa
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

3.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.

Authors:  W R Drobyski; C A Keever; M S Roth; S Koethe; G Hanson; P McFadden; J L Gottschall; R C Ash; P van Tuinen; M M Horowitz
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

4.  Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.

Authors:  D L Porter; M S Roth; C McGarigle; J L Ferrara; J H Antin
Journal:  N Engl J Med       Date:  1994-01-13       Impact factor: 91.245

5.  Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia.

Authors:  R Champlin; J Jansen; W Ho; J Gajewski; S Nimer; K Lee; M Territo; D Winston; G Tricot; T Reichert
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

6.  Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.

Authors:  W R Drobyski; R C Ash; J T Casper; T McAuliffe; M M Horowitz; C Lawton; C Keever; L A Baxter-Lowe; B Camitta; F Garbrecht
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

7.  Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?

Authors:  S Mackinnon; E B Papadopoulos; M H Carabasi; L Reich; N H Collins; R J O'Reilly
Journal:  Bone Marrow Transplant       Date:  1995-04       Impact factor: 5.483

8.  Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma.

Authors:  R Haas; R Möhle; S Frühauf; H Goldschmidt; B Witt; M Flentje; M Wannenmacher; W Hunstein
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

9.  Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission.

Authors:  T De Witte; B Awwad; J Boezeman; A Schattenberg; P Muus; J Raemaekers; F Preijers; P Strijckmans; C Haanen
Journal:  Bone Marrow Transplant       Date:  1994-11       Impact factor: 5.483

10.  Effect of GVHD on the recovery of NK cell activity and LAK precursors following BMT.

Authors:  C A Keever; J Klein; N Leong; E A Copelan; B R Avalos; N Kapoor; I Cunningham; P J Tutschka
Journal:  Bone Marrow Transplant       Date:  1993-09       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.